dc.contributor.author | Gaiottino, J | |
dc.contributor.author | Norgren, N | |
dc.contributor.author | Dobson, R | |
dc.contributor.author | Topping, J | |
dc.contributor.author | Nissim, A | |
dc.contributor.author | Malaspina, A | |
dc.contributor.author | Bestwick, JP | |
dc.contributor.author | Monsch, AU | |
dc.contributor.author | Regeniter, A | |
dc.contributor.author | Lindberg, RL | |
dc.contributor.author | Kappos, L | |
dc.contributor.author | Leppert, D | |
dc.contributor.author | Petzold, A | |
dc.contributor.author | Giovannoni, G | |
dc.contributor.author | Kuhle, J | |
dc.date.accessioned | 2019-01-22T16:00:19Z | |
dc.date.available | 2013-08-08 | |
dc.date.available | 2019-01-22T16:00:19Z | |
dc.date.issued | 2013-09-20 | |
dc.identifier.citation | Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, et al. (2013) Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE 8(9): e75091. https://doi.org/10.1371/journal.pone.0075091 | en_US |
dc.identifier.issn | 1932-6203 | |
dc.identifier.other | UNSP e75091 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/54859 | |
dc.description.abstract | Neuronal damage is the morphological substrate of persisting neurological disability. Neurofilaments (Nf) are cytoskeletal proteins of neurons and their release into cerebrospinal fluid has shown encouraging results as a biomarker for neurodegeneration. This study aimed to validate the quantification of the Nf light chain (NfL) in blood samples, as a biofluid source easily accessible for longitudinal studies.
Methods
We developed and applied a highly sensitive electrochemiluminescence (ECL) based immunoassay for quantification of NfL in blood and CSF.
Results
Patients with Alzheimer’s disease (AD) (30.8 pg/ml, n=20), Guillain-Barré-syndrome (GBS) (79.4 pg/ml, n=19) or amyotrophic lateral sclerosis (ALS) (95.4 pg/ml, n=46) had higher serum NfL values than a control group of neurological patients without evidence of structural CNS damage (control patients, CP) (4.4 pg/ml, n=68, p<0.0001 for each comparison, p=0.002 for AD patients) and healthy controls (HC) (3.3 pg/ml, n=67, p<0.0001). Similar differences were seen in corresponding CSF samples. CSF and serum levels correlated in AD (r=0.48, p=0.033), GBS (r=0.79, p<0.0001) and ALS (r=0.70, p<0.0001), but not in CP (r=0.11, p=0.3739). The sensitivity and specificity of serum NfL for separating ALS from healthy controls was 91.3% and 91.0%.
Conclusions
We developed and validated a novel ECL based sandwich immunoassay for the NfL protein in serum (NfLUmea47:3); levels in ALS were more than 20-fold higher than in controls. Our data supports further longitudinal studies of serum NfL in neurodegenerative diseases as a potential biomarker of on-going disease progression, and as a potential surrogate to quantify effects of neuroprotective drugs in clinical trials. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Public Library of Science | en_US |
dc.relation.ispartof | PLOS ONE | |
dc.rights | Creative Commons Attribution License | |
dc.rights | 2013 Gaiottino et al. | |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject | Neurofilaments | en_US |
dc.subject | Neurodegenerative Neurological Diseases | en_US |
dc.title | Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1371/journal.pone.0075091 | |
dcterms.dateAccepted | 2013-08-08 | |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |